Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Mayar Capital Abdulaziz A. Alnaim | “We also initiated two new positions in Lonza Group AG. Lonza is one of the highest-quality businesses we have studied in years, and we studied it hard before buying. It is the world's leading contract manufacturer of biologic medicines, the company big pharmaceutical firms hire to make their most complex drugs at scale. Once Lonza is making a medicine, it is written into the customer's regulatory filings and supply chain so deeply that switching becomes slow, costly and risky, which gives it the durable pricing power and customer retention we prize. It sits on a long tailwind too, as more of the drug pipeline shifts to biologics and as pharma increasingly chooses to outsource manufacturing rather than build it. Lonza has just completed its transformation into a focused, pure-play manufacturer, shedding its lower-quality ingredients division, and it guides to low-teens growth with expanding margins. It is not cheap on a simple multiple, and I won't pretend otherwise, but quality like this rarely is. Our own probabilistic work gave us the conviction that the price still leaves a margin of safety against the value we expect it to compound over the years ahead.” | NEUTRAL | Q2 2026 Jul 25, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
